Recent News
As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to pharmacotherapy - a reversal of the traditional model. This has with direct implications for how we counsel obese patients we start or co-manage on these agents.Read Article
CLOAK study: 3 mos DBRPCT of Colchicine vs PBO (no NSAID) in 120 symptomatic KOA (KL gr 2/3) shows no benefit in VAS pain index knee after 3 mos. (but COL pts had signif change in some biomarkers hsCRP, β-NGF (p < 0.05); PGE2, IL-1ra, IL-8, and VEGF (p < 0.16). https://t.co/MPgLpr7LPP
Dr. John Cush @RheumNow ( View Tweet)
Rheum Survey>> Which obesity treatment has the greatest safety concern(s)? Click here to respond>> https://t.co/jDpVe7u9Pu https://t.co/RNftdQlU1N
Dr. John Cush @RheumNow ( View Tweet)
17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vX https://t.co/EqRwpT8Sxo
Dr. John Cush @RheumNow ( View Tweet)
Join us for Tuesday Nite Rheumatology on September 22 for:
🔴 Obesity Treatment & Safety
Experts will tackle:
• GLP-1/GIP therapies
• Lifestyle & bariatric interventions
• Treatment selection & safety
• Cost & compounding concerns
• Sarcopenia & bone health
• The future https://t.co/YNEsGofRR9
Dr. John Cush @RheumNow ( View Tweet)
Observational study of 63,215 neuropsychiatric (NP) pts showed semaglutide signif lowered NP events over 2yrs (vs metformin, SGLT2 inhibitors, DPP-4 inhib);unrelaed to wt loss. Less substance, mood anxiety, CNS atrophies, neuromuscular, eating/sleep & personality/impulse-control https://t.co/tbuvLRK3QE
Dr. John Cush @RheumNow ( View Tweet)
EBR Journal Club: Obexelimab in IgG4-Related Disease (INDIGO)
The EBR Journal Club Companion applies my adapted JAMA approach to critical appraisal to an important rheumatology RCT. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How https://t.co/rH7BY21FvF
Dr. John Cush @RheumNow ( View Tweet)
Obesity management goes far beyond the number on the scale.
Watch our Four Pillars of Weight Loss video series, part of this month’s The Obesity Imperative campaign.
What Are the Four Pillars of Obesity Management?
Building a Multidisciplinary Program for Obesity & Arthritis https://t.co/3tjeST1wWs
Dr. John Cush @RheumNow ( View Tweet)
n the updated ACR osteoarthritis guidance, methotrexate received a conditional recommendation for which OA subtype: hip OA; knee OA; erosive hand OA; or axial OA?
Test your knowledge in the latest RheumIQ quiz at https://t.co/LHFv1P6XZe.
Dr. John Cush @RheumNow ( View Tweet)
Added IVIG is Effective in Myositis
A small randomized controlled trial demonstrates that intravenous immunoglobulin (IVIG) added to cortocosteroids lead to greater and faster improvements in patients with newly diagnosed IIMs.
https://t.co/XLrvLSoOic https://t.co/xhjPBXLxiC
Dr. John Cush @RheumNow ( View Tweet)
True or False: According to a metanalysis of 87 studies, higher BMI and smoking were linked to reduced methotrexate efficacy in rheumatoid arthritis. Check your knowledge in the latest RheumIQ quiz at https://t.co/LHFv1P6XZe.
Dr. John Cush @RheumNow ( View Tweet)
Discussing Weight Loss: 3 Minute Script
Dr. Jack Cush's 3 Minute Script as discussed in his Introducing Weight Loss video.
https://t.co/JRWAPc5if5 https://t.co/jI65VzTIfs
Dr. John Cush @RheumNow ( View Tweet)
Chinese 52 wk study of XKH004, a novel, SC, humanized anti-17A/F in 323 active AS pts Rx q4 wks vs PBO. @ Wk 16, XKH004 was superior for ASAS40 (45.4% vs 19.4%; P<0.001), improved to 66% by wk 52. https://t.co/f7w41m4QZy https://t.co/LELo52zUb7
Links:
Dr. John Cush @RheumNow ( View Tweet)
Obesity and Rheumatic Disease
Presented as part of RheumNow's "The Obesity Imperative" campaign.
https://t.co/d2fl4EJX8Q https://t.co/AZGfKRvZrx
Dr. John Cush @RheumNow ( View Tweet)
Early RA Referral Clinics Work (9.18.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read Article
Join us for Tuesday Nite Rheumatology on September 22 for:
Obesity Treatment & Safety
Experts will tackle:
• GLP-1/GIP therapies
• Lifestyle & bariatric interventions
• Treatment selection & safety
• Cost & compounding concerns
• Sarcopenia & bone health
• The future of https://t.co/BCSOUot5FL
Dr. John Cush @RheumNow ( View Tweet)
Review of HLA-B27
What’s New? HLA-B27 remains the dominant genetic link to spondyloarthritis (SpA) across the age spectrum, but B27 related clinical expression diverges between children and adults. New mechanistic data on autoreactive T cells, HLA-B27 misfolding, and gut-joint https://t.co/13hbXlAvCr
Dr. John Cush @RheumNow ( View Tweet)
Added IVIG is Effective in Myositis
A small randomized controlled trial demonstrates that intravenous immunoglobulin (IVIG) added to cortocosteroids lead to greater and faster improvements in patients with newly diagnosed idiopathic inflammatory myopathies (IIMs). https://t.co/uNNJ9sHU8M
Dr. John Cush @RheumNow ( View Tweet)
Bariatric Surgery in the Era of GLP-1RA
Overweight/obesity is a chronic multi-system disease that can impair physical and mental health. It now affects almost 1 in 3 Canadians. Multiple recent guidelines have therefore suggested using waist measurements, in addition to BMI, to https://t.co/RaXnQ2d9Yr
Dr. John Cush @RheumNow ( View Tweet)
4,197 pts from the UK Biobank met fibromyalgia criteria, yet 72.6% had NOT received a diagnosis. Non-Dx assoc w/ male, older age, milder sxs or other pain Dx (OA, CRPS, CFS), lower polysymptomatic distress scores, and less frequent fatigue. https://t.co/Y9m9jR5wbR https://t.co/fitm675kyK
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
A few years ago, when I would see a patient with rheumatic disease and increased BMI, I would often document it as obesity as a comorbidity, recommend weight loss and exercise, and then move on. My approach has changed.
Read Article
Podcasts
The Four Pillars of Weight Loss Part 1
Obesity QD Clinics Part Two
Early RA Referral Clinics Work (9.18.2026)-
Obesity QD Clinics Part One
Therapeutic Updates
The Four Pillars of Weight Loss
RheumNow
Watch our 'Four Pillars of Weight Loss' series as part of this month's The Obesity Imperative campaign. Videos include: 'Building A Multidisciplinary Program for Obesity and Arthritis Management' and "Nutrition, Weight Management and Rheumatic Disease".
Read Post
Label update: Structural damage progression in active PsA
Sponsored by Johnson & Johnson Medical Affairs
Listen to Dr. Catherine Bakewell’s review of clinical data from a recent label update.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years
Daily Gem
Obesity can escalate pain, function and disease activity scores.
--